Una compañía biofarmacéutica global líder
Mayor rapidez al pico de ingresos
Ingresos heredados preservados
Adelanto sobre el plan
Desafío
Ante la caducidad de patentes de dos terapias estrella, debía acelerar lanzamientos oncológicos de nueva generación y maximizar los ingresos restantes de marcas maduras en 30 mercados.
Enfoque
We redesigned the go-to-market model around omnichannel engagement, deploying AI-driven physician targeting and next-best-action engines. We restructured the commercial organization from geography-based to therapeutic-area-aligned teams and built a launch excellence playbook that reduced time-to-peak-revenue by 40%.
Impacto
The first new therapy launched reached peak-year revenue projections 18 months ahead of plan. Legacy brand managed decline was slowed by 25%, preserving $1.2 billion in cumulative revenue over three years.